Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2021 Webinar: Practical Approach to Coagulation Management in Cirrhosis

    Contains 2 Component(s) Recorded On: 01/11/2021

    Webinar hosted by the Clinical Practice Special Interest Group on January 11, 2021.

    Coagulation disorders in patients with cirrhosis present challenging situations for clinical providers. This one hour webinar will summarize the knowledge behind coagulation disorders in patients with cirrhosis, including the mixed and thrombosis prone model, limitations in current tests of hemostasis, and the dangers of excessive transfusion. Using practical clinical vignettes, learners will gain understanding of best practice to manage these difficult coagulation situations, including in practice settings where colleagues in hospital medicine and interventional radiology may have different approaches. Vignettes will include an outpatient cirrhotic patient with portal vein thrombosis, an inpatient cirrhotic requiring paracentesis, and an inpatient cirrhotic in the intensive care unit with renal failure and spontaneous mucosal bleeding.

    Nicolas Intagliata

    Nicolas Intagliata, MD is an associate professor of medicine at the University of Virginia. His research is based in hemostasis and liver disease. More specifically, the role of anticoagulation in prevention and treatment of thrombosis in cirrhosis and underlying mechanisms of hemostasis and thrombosis in liver disease. His clinical practice involves caring for patients both in the general hepatology and liver transplantation setting.

    Arul Thomas (Moderator)

    Arul M. Thomas, MD is an assistant professor of medicine at the MedStar Georgetown Transplant Institute at Georgetown University Hospital, in Washington, DC. He has interests in all aspects of clinical transplant hepatology, including autoimmune liver diseases, drug induced liver injury and pediatric to adult transition of care. He serves on the Clinical Practice SIG. He practices also at MedStar Washington Hospital Center, where he fulfills a goal to increase access to advanced liver care in underserved communities in the DC area. At all his clinical sites, he is well-known as an avid educator of trainees.

  • 2020 Webinar: Chronic Hepatitis C 500: The Advanced Course

    Contains 2 Component(s) Recorded On: 12/02/2020

    Webinar hosted by the Hepatitis C Special Interest Group on December 2, 2020.

    Many HCV-infected patients suffer from decompensated cirrhosis. Aside from appropriate care of their cirrhosis, these patients may benefit from therapy, irrespective of liver transplant candidacy. Providers outside of transplant centers, should be knowledgeable about pertinent aspects of liver transplants for their patients. Finally, several groups have reported unusual genotype subtypes which are less responsive to existing DAA regimens. This webinar is designed for the experienced HCV-treatment provider.

    Brian Pearlman

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

    Preeti A. Reshamwala

    Preeti A. Reshamwala, MD is a Distinguished Physician in Transplant Hepatology at Emory University School of Medicine. She is the director of The Fatty Liver Clinic, and the program director for the Transplant Hepatology Fellowship Program.

    Dr. Reshamwala has participated in over 21 clinical trials on the treatment of Hepatitis C. She co-directs the management and treatment of patients with hepatitis C who are on the waitlist for liver transplantation at Emory University, and hepatitis C treatment for patients after transplantation. She has been an advocate for using hepatitis C positive donors for liver transplant recipients who have not been exposed to Hepatitis C.

    Jean-Michel Pawlotsky

    Jean-Michel Pawlotsky, MD, PhD is professor of medicine at the University of Paris-Est. He is the director of the National Reference Center for Viral Hepatitis B, C and D and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and director of research team “Viruses-Hepatology-Cancers“ at the Mondor Institute of Biomedical Research (INSERM U955). He focuses on teaching and research in virology (primarily hepatitis viruses) and liver oncology. Dr. Pawlotsky earned his medical degree in Hepatology and Gastroenterology in 1992. In addition, he earned a Thesis in molecular virology from the University of Paris, France, and he is a graduate in virology from the Pasteur Institute in Paris and microbiology from the University of Paris. Dr. Pawlotsky has been acting as the Secretary General of the European Association for the Study of the Liver (EASL) between 2005 and 2009.

    Dr. Pawlotsky is a member of the Strategic Committee of the National Agency for Research on AIDS and Viral Hepatitis (ANRS). He has been an associate editor of HEPATOLOGY, the official journal of the American Association for the Study of Liver Diseases (AASLD), between 2001 and 2006, and an associate editor of Gastroenterology, the official journal of the American Gastroenterological Association (AGA), between 2011 and 2016. Dr. Pawlotsky’s noted career contributions include the publication of over 500 articles and book chapters in his areas of expertise and over 650 invited lectures at international meetings.

    Omar Massoud (Moderator)

    Omar Massoud, MD, PhD, FAASLD is an associate professor of medicine at the University of Alabama at Birmingham. He is the director of clinical liver research at the University of Alabama Liver Center. He is a member of the AASLD Publication Committee and Hepatitis C Special Interest Group Steering Committee. He earned his Doctor of Medicine degree from Al-Azhar University, Cairo, Egypt. He completed residency in Internal Medicine at Case Western Reserve University, Cleveland, Ohio, followed by Fellowship in Gastroenterology and Hepatology at the Medical College of Wisconsin, Milwaukee, Wisconsin. He completed a fellowship in Transplant Hepatology at Mayo Clinic, Rochester, Minnesota.

    Dr. Massoud was the PI of the large CDC study on Birth Cohort HCV screening (2011-2016). The results of this study lead to change in HCV screening national guidelines. He is also the PI of several government and industry sponsored studies on HCV and NASH. He has numerous publications and presentations on HCV and NASH. He mentored many trainees and young faculty throughout their career.

    Photo of Omar Massoud, MD, PhD, FAASLD

  • Fundamentals of Liver Disease - Hepatitis B 2.0

    Contains 25 Component(s), Includes Credits Recorded On: 10/15/2020

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front-line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:

    HBV: Epidemiology and Screening
    Patient with Positive Hepatitis B Serologies
    Natural History of HBV and Identification of Treatment Candidates
    Management of the Chronic HBV Patient with Co-morbid and Other Conditions
    Antiviral Treatment of the Patient with Chronic HBV
    Prevention of HBV Infection
    Hepatitis B in the Pediatric Patient

    Release date: October 15, 2020
    Expiration date: October 14, 2023
    Time to complete each module: 30 minutes

    CREDITS OFFERED

    Continuing Medical Education (CME): For a maximum of 3.50 AMA PRA Category 1 Credits™   
    Continuing Education (CE): For a maximum of 3.50 Contact Hour 
    You may only earn one Continuing Education Credit type- either CE or CME

    Maintenance of Certification (MOC): For a maximum of 3.50 MOC Points


    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:

    -7 online interactive, narrated modules 20 to 30 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objectives:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 3.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 3.50 MOC Points
    Continuing Education (CE): For a maximum of 3.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 3.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 3.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 3.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by October 14, 2023

    CLAIMING CE CREDITS
    Nurses for a maximum of 3.50 contact hours for this enduring continuing education material must be completed by October 14, 2023

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by October 14, 2023. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through October 2023 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    Marc G. Ghany

    Marc G. Ghany, MD, MHSc, FAASLD is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    Tram T. Tran

    Tram T. Tran, MD, FAASLD is the Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Norah A. Terrault

    Norah A. Terrault, MD, MPH, FAASLD is a Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a master’s in public health at the University of California at Berkeley. 

    Dr. Terrault has focused her clinical and research activities on viral hepatitis and non-alcoholic fatty liver disease, especially in special populations including those with cirrhosis and those with transplants. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and fatty liver, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIH-supported HBV clinical research network (HBRN) and nonalcoholic steatohepatitis clinical research network (NASH CRN). She has authored 330 peer-reviewed manuscripts, editorials, invited reviews as well as US national guidelines for treatment of chronic hepatitis B and C. She is past associate editor for Hepatology and deputy editor for Liver Transplantation and co-edited Zakim and Boyer’s textbook in hepatology. 

    Dr. Terrault is the founder of ECHO-Plus, a multifaceted program to train and support primary care physicians in California to care for patients with hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators. Dr. Terrault was recently elected as Councilor to the AASLD governing board and will serve as president in 2023.

    Marion G. Peters

    Marion G. Peters, MBBS, MD, FAASLD is an Emeritus Professor of Medicine at the University of California at San Francisco and Adjunct Professor of Medicine at Northwestern University, Chicago. She is a hepatologist with a particular interest in viral hepatitis in complicated clinical settings, patients with co-morbid conditions including alcoholism and HIV infection.  She led the NIH AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group (TSG) for 4 years where she championed young investigators to be chairs of new trials in Hep TSG. She is the Protocol Facilitator for ACTG Hepatitis TSG HBV-related studies, focusing on the development of US and international studies for new drugs for patients with HBV, with and without HIV. She is currently a team member or co-chair of 4 ACTG hepatitis trials. She is also a member of the HEP TSG steering committee.

    Dr. Peters serves on the scientific Advisory Board of International Antiviral Society USA, HEP DART and is a senior advisor to International Coalition to Eliminate HBV. She is an editor for the Journal of Antimicrobial Chemotherapy. She has trained fellows, house staff and medical students in clinical and translational research, many of whom have gone on to faculty positions focusing on liver disease. She has mentored faculty and fellows in her institution, nationally and internationally. She is particularly focused on mentoring women in medicine.  She has numerous publications on viral hepatitis with and without HIV coinfection in peer-reviewed journals with multiple collaborators.




    Anna S. Lok

    Anna S. Lok, MD, FAASLD graduated from the University of Hong Kong Medical School. She completed her hepatology training in London under Dame Sheila Sherlock.  She joined the University of Michigan in 1995 as Director of the Hepatology Program. She became Associate Chair for Clinical Research in the Department of Internal Medicine in 2008 and Assistant Dean for Clinical Research in 2016. 

    Dr. Lok’s research focuses on natural history and treatment of hepatitis B and C. She has published more than 550 papers on viral hepatitis and liver diseases including the American Association for the Study of Liver Diseases (AASLD) guidelines on “Hepatitis B”. She also participated in the development of the first World Health Organization guidelines on hepatitis B and C. Dr. Lok has made important contributions to the understanding of factors influencing the progression of hepatitis B and C, and the development of new treatments of these diseases. 

    Dr. Lok received many awards throughout her career including the Distinguished Scientist Award from the Hepatitis B Foundation in 2008, the Distinguished Service Award from the AASLD in 2011, the William Beaumont Prize in Gastroenterology from the American Gastroenterological Association in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver and an Hon DSc from the University of Hong Kong in 2017, an International Recognition Award from the European Association for the Study of the Liver in 2018, and a Distinguished University Professorship from the University of Michigan in 2019. 

    Dr. Lok served as Associate Editor of HEPATOLOGY in 2002-6, co-Editor of Journal of Viral Hepatitis in 2007-9, Senior Associate Editor of GASTROENTEROLOGY in 2011-2012, and President of AASLD in 2017. 

    Brian McMahon

    Brian J. McMahon MD, FAASLD is Director of the Liver Disease and Hepatitis Program at the Alaska Native Medical Center (ANMC) in Anchorage, Alaska. Dr. McMahon has served as co-author of the AASLD Practice Guideline for Hepatitis B between 2009 and 2018 and is co-Author of the AASLD Hepatitis B Guidance 2019. He was also the co-chair of the WHO Hepatitis Guideline published in 2015. He directed a program that halted transmission of hepatitis B in the Alaska Native population in the 1980’s, the only US born population endemic for persons with chronic hepatitis B. He oversees the management and care of over 1,000 Alaska Native persons with chronic hepatitis B.

    Dr. McMahon has served on the editorial board of Hepatology. He was previously chair of the AASLD Practice Guidelines Committee, was on the AASLD Nominating Committee and was previously chair of the Hepatitis B SIG. He received the AASLD distinguished Mentor/Clinician Award for 2017 for contributions in the global elimination of hepatitis B. He has received multiple NIH and CDC research grants and directs a team of investigators in Alaska. He conducts research in Alaska Native People including hepatitis A and B vaccine long-term efficacy, hepatitis B and C outcome, autoimmune liver diseases and NAFLD. He also has been involved in two hepatitis B projects funded by the Global AIDS program and the CDC Foundation in Tanzania and Zanzibar Africa. He teaches medical students at the University of Alaska/University of Washington WWAMI program, precepts medical students, residents in hepatology clinic and mentors medical students’ research projects. He holds a position as a Research Associate at the Arctic Investigations Program of the CDC located on the ANMC campus in Anchorage. He is Clinical Professor of Medicine at the University of Washington, School of Medicine in Seattle and Auxiliary Professor of Health Sciences at the University of Alaska, Anchorage. He has published over 160 peer review original articles plus over 50 review articles, guidelines/guidance statements and editorials.

    Maureen M. Jonas

    Maureen M. Jonas, MD, FAASLD is the Director of the Center for Childhood Liver Disease in the Division of Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital, and Professor of Pediatrics at Harvard Medical School.  Her area of expertise is Pediatric Hepatology and Liver Transplantation, with a special emphasis on viral hepatitis in children. She is the author of a number studies of therapies for pediatric viral hepatitis.

    Dr. Jonas has served on several AASLD committees, including the Practice Guidelines Committee, Ethics Committee and Nominating Committee.  She chaired several symposia sponsored by AASLD and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition at AASLD annual meetings.  She has served as abstract reviewer for AASLD meetings, and ad hoc reviewer for Hepatology.  Jonas established the Pediatric Transplant Hepatology training Program at Boston Children’s Hospital and served as its director until 2016.  She was the Medical Director of the Liver Transplant Service at BCH from 1991 through 2014. As an active educator, she has mentored numerous pediatric gastroenterology and hepatology fellows, as well as junior faculty, over the last 30 years.  She currently serves on the Transplant Hepatology Examination Committee for the American Board of Pediatrics.  She has been the lead Principal Investigator for many multinational pediatric viral hepatitis trials and has lectured extensively on this topic around the country and around the world.

    DISCLOSURE OF CONFLICTS OF INTEREST 
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Marc G. Ghany, MD, MHSc, FAASLD
    Faculty
    Nothing to disclose

    Tram T. Tran, MD, FAASLD
    Faculty
    Employment: Gilead Sciences (Unrelated)

    Norah Terrault, MD, MPH, FAASLD
    Faculty
    Grant/Research Support: Gilead Sciences and Roche/Genetech

    Marion G. Peters, MD, FAASLD
    Faculty
    Faculty/Advisory Committee or Review Panels: Antios, Atea and Aligos
    Employment (Spouse): Genentech Research and Development (subsidiary of Roche)

    Anna S.F. Lok, MD, FAASLD
    Faculty
    Advisory Board: CLEAR-B, Gilead Sciences, GlaxoSmithKline, Huahui, Roche, Spring Bank, and TARGET PharmaSolutions
    Grant/Research Support: Assembly Biosciences, Bristol Myers Squibb, Gilead Sciences, and TARGET PharmaSolutions (to University of Michigan)

    Brian J. McMahon, MD, FAASLD
    Faculty
    Grant/Research Support: Gilead Sciences - Grant received by department at institution and not directly.

    Maureen M. Jonas, MD, FAASLD
    Faculty/Advisory Committee or Review Panels: Served as chair of DSMB for Gilead Sciences
    Grant/Research Support: AbbVie, Gilead Sciences, Roche and Merck. Echosens (equipment only)

    Lauren A. Beste, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Nothing to disclose 

    Amanda J. Chaney, DNP, APRN, FNP-BC 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Royalities: Springer Publishing-Author 

    Leslie Hayes, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Nothing to disclose 

    Vicki Shah, PA 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board 

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Denise Seise 
    AASLD Staff 
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff 
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.


  • 2020 Webinar: Treatment Strategies for Autoimmune Hepatitis Beyond First-line Therapy

    Contains 2 Component(s) Recorded On: 10/14/2020

    Webinar hosted by the Cholestatic and Autoimmune Liver Diseases Special Interest Group on October 14, 2020.

    Treatment failure. Incomplete response. Treatment intolerance. Management of autoimmune hepatitis can be extremely challenging when first-line therapy is inadequate. Join us for a discussion of alternative treatment options for autoimmune hepatitis and a review of their efficacy. Learn about updates to the treatment paradigm from the new 2019 guidelines!

  • 2020 Webinar: Novel Models for HCV Care Delivery

    Contains 2 Component(s) Recorded On: 10/06/2020

    Webinar hosted by the Hepatitis C Special Interest Group on October 6, 2020.

    In order to achieve the World Health Organization's goal of treating at least 80% of identified HCV-infected patients, novel models of HCV care delivery should be implemented. This webinar will address telemedicine and digital telemedicine with respect to HCV care and will attempt to demonstrate improved models of linkage to care in both urban and exurban settings.

    John D. Scott

    John Scott, MD, MSc is a Professor of Medicine (Division of Allergy and Infectious Diseases) and Medical Director of Digital Health at the University of Washington. He graduated from Stanford University with a degree in Human Biology, attended Georgetown University School of Medicine cum laude, completed a residency in Internal Medicine at Stanford University Hospitals, and then obtained sub-specialty training in Infectious Diseases at the University of Washington.

    In 2009, he launched Project ECHO (Extension for Community Health Outcomes) in Washington State, the first place to replicate the ECHO model outside of New Mexico. This innovative telehealth program helps clinicians serving in rural and underserved areas with the evaluation and treatment of common, complex, chronic diseases. In 2015, he won the Warren Reid Award for excellence in health care for the state of Washington, in recognition of his telehealth work. He chairs the Washington State Telehealth Collaborative and serves on the Telehealth committee for the Infectious Disease Society of America.

    Jennifer C. Price

    Jennifer Price, MD, PhD is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and Director of the UCSF Viral Hepatitis Center. Her research examines the contributions of novel and traditional factors associated with liver disease and fibrosis progression in large observational HIV cohorts, with or without viral hepatitis. Dr. Price is a PI of the San Francisco Bay Area site of the Multicenter AIDS Cohort Study (MACS)/Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS), which integrates two of the largest and longest running NIH-funded prospective cohorts of men and women with and at risk for HIV in the U.S. She also serves as co-Chair of the MWCCS Liver Working Group and Vice Chair of the AASLD HCV SIG. Dr. Price is a member of the End Hep C SF Coordinating Committee and leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She is the founding director of the DeLIVER Care Van, a mobile unit aimed at improving access to HCV screening and high-quality liver-related health care among marginalized communities.

    Sally Hodder

    Sally Hodder, MD is a Professor Medicine, Associate Vice President for Clinical and Translational Research at West Virginia University and Director and Principal Investigator (PI) of the West Virginia Clinical and Translational Science Institute. A graduate of Case Western Reserve University School of Medicine, she has been on the front lines of the HIV epidemic since she was an intern at the University of California San Francisco in 1980. After completing infectious diseases fellowship training, she saw first-hand the emergence of AIDS in Africa while working on a Schistosomiasis haematobium project in Coast Province, Kenya. Subsequently, she has had extensive experience leading large scientific programs (both academia and pharma). From 2003-2005, she served as Vice President of Virology Medical Affairs, Bristol-Myers-Squibb. In 2005, Dr. Hodder was recruited to New Jersey Medical School in Newark, New Jersey to build an HIV program where HIV prevalence was nearly 3% among the African American community. She served as Medical Director for a large HIV clinic in Newark and was successful in obtaining funding for both HIV treatment and prevention trials. She served as Protocol Chair for the NIH-funded HIV Prevention Trials Network 064 trial, a study of HIV incidence and risk behaviors among 2,099 U.S. women. In 2014, West Virginia University recruited Dr. Hodder to direct and serve as Principal Investigator of the West Virginia Clinical and Translational Science Institute, funded by the NIH. During her tenure, the West Virginia Practice-Based Research Network was developed which now includes 107 primary care sites across West Virginia, the Extension for Community Healthcare Outcomes (ECHO) to enhance rural primary care providers’ knowledge was implemented, and opioid use disorder and resultant emergent epidemics (e.g., hepatitis B, C, and HIV) were made a programmatic focus. She again finds herself on the front lines as HIV outbreaks are emerging in West Virginia.

    Lisa Catalli (Moderator)

    Lisa Catalli is a Nurse Practitioner at the University of California, San Francisco’s Viral Hepatitis Center and Liver Transplant Clinic. She earned her Master’s Degree from UCSF School of Nursing in 1995 and has been working in the field of Hepatology since 2010. She has been treating HCV since the dawn of direct-acting antiviral therapy, and served as a co-investigator in several multi-center clinical trials. Her expertise in HCV treatment has led to multiple educational and leadership activities in HCV elimination. She has worked to disseminate knowledge about HCV through mentoring students and didactic presentations and workshops. She is a key clinical faculty in the UCSF Project ECHO program which uses multi-point video conferencing to build knowledge-sharing networks with community providers to build the capacity for care of HCV patients throughout California.

    She is also part of an interdisciplinary team to improve access and linkage to HCV care through a creative, innovative model of mobile liver care clinic (UCSF DeLiver Care) that is co-localized at syringe exchange/medically assisted treatment centers for vulnerable populations. She has been a Hepatology Associates member of AASLD for 10 years with leadership roles in the HCV SIG and the Hepatology Associates Committee, serving on committees for the planning of AASLD educational programs, moderating educational sessions, and selecting NP/PA fellowship awards.

  • 2020 Transplant Hepatology Board Review Course

    Contains 34 Component(s), Includes Credits Recorded On: 09/23/2020

    This course will help prepare physicians for the ABIM and ABP certification and MOC exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint.

    The 2020 AASLD Transplant Hepatology Board Review Course set for August 15-16 in Dallas, TX is now an on-demand course. This on-demand course will release on Friday, August 15, 2020.  For further questions contact education@aasld.org. 

    This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
    - 25 online, narrated presentations 20 - 45 minutes in length 
    - MOC quiz questions for each session
    - Evaluation for CME credit/ABIM and ABP MOC point offerings 

    DIRECTIONS
    Review all section tabs before you begin. Start watching the presentation videos. Complete necessary components to claim either CME and ABIM and or ABP MOC.

    HANDOUTS
    To access, download and print the PDFs of each presentation, please head to the Handouts tab.  Note, you will need to download the PDF to your device to proceed with printing. 

    COURSE FEEDBACK
    Once you have watched the content, come and share your questions and feedback by heading to the course's AASLD Engage Page.  Based on the feedback from the AASLD Engage page and the supplemental survey to be sent in late August, AASLD might host real-time Q&A webinars based on your comments and questions about the content in mid-September.

    PRICING
    Member ------------------$325
    Nonmember -------------$540
    Associate Member ------$185
    Associate Nonmember -$235
    Student Member ---------$90
    Student Nonmember ---$115
    Trainee Member --------$185
    Trainee Nonmember ---$235
    Industry-------------------$775

    CANCELLATION POLICY (Ended August 14, 2020)

    Requests for cancellation must be submitted in writing to meetings@aasld.org. Cancellations received:

    - Through August 14, 2020 at 11:59PM are subject to a $75.00 cancellation fee.
    - August 15, 2020 and after are non-refundable.

    CONTINUING EDUCATION 
    Continuing Medical Education (CME): 9.25 AMA PRA Category 1 Credits™
    ABIM Maintenance of Certification (MOC): 9.25 ABIM MOC Points
    ABP Maintenance of Certification (MOC): 9.00 ABP MOC Points

    HOW TO EARN AND CLAIM MOC POINTS
    To claim both CME Credits and ABIM and or ABP MOC points for this activity you must:  

                 o    Watch each video presentation
                 o    Complete each session post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.   
                 o    Complete the Final Evaluation
                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.
    MOC points are available for ABIM and or ABP board certified physicians only.

    Release Date: August 15, 2020
    Expiration Date: December 31, 2022

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    Andrew I. Aronsohn

    Andrew Aronsohn is an Associate Professor of Medicine in the Center for Liver Diseases at the University of Chicago Medical Center. Dr. Aronsohn is the program director for the Gastroenterology fellowship at the University of Chicago. In addition, Dr. Aronsohn is a faculty member at the MacLean Center for Clinical Medical Ethics at the University of Chicago and is the co-director of the Pritzker School of Medicine Doctor Patient Relationship course.  Dr. Aronsohn research interests involve HCV education, access to care and elimination. He is the co-principal investigator of HepCCATT, an initiative to diagnose, link to care and treat HCV in the Chicago area. This project utilizes telehealth technology to expand HCV management into the primary care setting.  Dr. Aronsohn is the co-lead of the treatment experienced section of the AASLD / IDSA HCV guidance writing committee as was a member of National Academies of Medicine committee which wrote “A National Strategy for the Elimination of Hepatitis B and C”. He also has a busy clinical practice, which includes both general and transplant hepatology.

    Oren K. Fix

    Dr. Oren Fix is the Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle, Washington, Clinical Associate Professor at the Washington State University Elson S. Floyd College of Medicine, and Associate Provider Informaticist at Providence St. Joseph Health. He is board certified in Transplant Hepatology, Gastroenterology, Internal Medicine, and Clinical Informatics. He is the co-chair for the AASLD COVID-19 Task Force's Clinical Oversight Subcommittee, and serves on the AASLD Nominating Committee, Online Learning Committee, and the GI/Transplant Hepatology Pilot Steering Task Force. He is on the editorial boards of Liver Transplantation and Hepatology Communications. Past service to AASLD includes chair of the Training and Workforce Committee and chair of the MOC Committee.

    Jacquelyn F. Fleckenstein

    Dr. Fleckenstein is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Washington University School of Medicine in St. Louis, Missouri.  She is interested in the management of advanced cirrhosis and pregnancy related liver disease.  She serves as the director of the liver transplant fellowship program at Washington University and she has served on several AASLD committees. 

    Catherine Frenette

    Catherine Frenette is the Medical Director of Liver Transplant at the Scripps Center for Organ Transplant, Scripps Green Hospital, La Jolla, CA. She is also the Medical Director of the Liver and Hepatocellular Cancer Program at the Scripps MD Anderson Cancer Center. Catherine underwent medical training at Rush Medical College in Chicago, IL. She then completed internal medicine training at Scripps Mercy Hospital in San Diego, CA, and subsequently underwent training in gastroenterology with a focus on transplant hepatology at Scripps Clinic in La Jolla, CA. Since joining Scripps in 2012, Catherine has worked diligently to provide excellent medical care to patients with end stage liver disease and liver cancer. In addition to directing two major medical programs in Southern California, Catherine has been the Principle or Co-Investigator for multiple clinical trials related to liver disease and liver cancer. She also serves a key role in the training of gastroenterology fellows, as well as internal medicine residents. Catherine has also served the community through the American Liver Foundation, where she serves as vice-chair of the local Medical Advisory Committee and is also on the National Executive Committee. She has been awarded Fellow Status of the American Society of Transplantation and has also been awarded Fellow of the American Gastroenterology Association.

    I have worked diligently in the transplant world for more than a decade, where I have been active in local and regional meetings, attending nearly every regional meeting in the past 12 years. I also have been active in meetings regarding policy, attending national meetings to discuss liver redistricting and participating in the American Transplant Society Liver and Intestinal Community of Practice Policies Subcommittee. I have a unique perspective regarding transplantation, because I am also a donor family member. This allows me to truly understand all parties involved in transplant, including the donor, the recipient, as well as the transplant programs and organ procurement organizations. I have served on many committees throughout my career and am committed to continuing to serve the transplant community as an Associate Councillor.

    Stevan A. Gonzalez

    Dr. Stevan Gonzalez is the medical director of liver transplantation at the Baylor Simmons Transplant Institute at the Baylor Scott & White All Saints Medical Center in Fort Worth, Texas. He is a graduate of Dartmouth Medical School and completed his training in internal medicine, gastroenterology, and hepatology at the New York-Presbyterian Weill Cornell Medical Center in New York, at which time he received a Master of Science degree in biostatistics at the Columbia University Mailman School of Public Health. He then completed a transplant hepatology fellowship at Stanford University Medical Center. He has worked as a transplant hepatologist with the Baylor program in Fort Worth and Baylor University Medical Center in Dallas since 2008, and has served as the medical director of liver transplantation at Baylor in Fort Worth since 2015. He has maintained an active role in organ transplantation, medical education, and research as an Associate Professor in the Department of Internal Medicine at the TCU and UNTHSC School of Medicine. His clinical and research interests include viral hepatitis and liver transplantation, portal hypertension, and kidney dysfunction in cirrhosis.

    Janice Jou

    Janice Jou, MD, MHS is a transplant hepatologist in the VA Portland Healthcare System and Associate Professor in the Division of Gastroenterology and Hepatology at Oregon Health and Science University. Dr. Jou is also the program director for the gastroenterology fellowship at OHSU and is actively involved in leading educational activities for the American Association for the Study of Liver Diseases and the American Gastroenterological Association. Her research interests include outcomes for hepatocellular carcinoma and processes of care in chronic liver disease.

    Laura M. Kulik

    I am a Professor of Medicine in the Division of Gastroenterology and Hepatology, and am Certified in both Gastroenterology and Hepatology and in Transplant Hepatology. My major clinical research focus is on the therapy and diagnosis of hepatocellular carcinoma. I work in a muliti-disciplinary medical/radiologic/surgical Liver Tumor clinic, and am involved in the recruitment of patients with HCC into clinical or pathologic trials. My major interest is on loco-regional therapy for HCC, both as a primary therapy and as a bridge to liver transplantation, including 90Yttrium radiotherapy and TACE.

    Josh Levitsky

    Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine where he was elected to Alpha Omega Alpha. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. At Northwestern, he completed a Master of Science in Clinical Investigation. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology.

    Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is a Deputy Editor for the American Journal of Transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. At Northwestern, he is currently the Gastroenterology Program Director and Director of Liver Research. He has been elected to the Feinberg Academy of Medical Educators and has received several teaching awards.

    Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation, American Association for the Study of Liver Diseases, and the International Liver Transplantation Society. He was previously a Councilor-At-Large for the American Society of Transplantation from 2014-2017. He was a prior chair of the American Transplant Congress, recent co-chair of AST’s CEOT meeting and is the current co-chair of the AST Education Committee. One of his passions is trainee education, establishing the AST Comprehensive Trainee Curriculum and regularly participating in the yearly Fellow’s Symposium. Dr. Levitsky’s dedication to the field of transplantation and AST includes all facets of clinical care, advocacy, research and education.

    Michael R. Lucey

    Dr Michael Ronan Lucey was born in Dublin, Ireland, and was educated at Trinity College, Dublin, graduating with the degrees of M.B., B.Ch in 1976.  He was awarded an M.D. by thesis in 1985. He completed his internship at the Meath Hospital, Dublin and residency in Internal Medicine at the Federated Dublin Voluntary Hospitals.  He was a fellow in Gastroenterology at Saint Bartholomew's Hospital, and a fellow in Liver Diseases in Kings College Hospital, both in London, England.  In 1985 he came to the University of Michigan, first as a fellow and then as faculty in the Division of Gastroenterology.  While at the University of Michigan, he became Medical Director of the liver transplant program.  From 1995 to 2001, he was Director of Hepatology at the University of Pennsylvania.  In 2001until the present,  he has been Professor of Medicine, Chief of the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine and Public Health. 

    Dr Lucey's research interests include selection for and outcome of liver transplantation, alcoholic liver disease, and management of end-stage liver disease.  Dr Lucey was president of the American Society of Transplantation in 2003. He was treasurer of the American Association for the Study of Liver Diseases from 2007 to 2010. 

    He was Editor in Chief of Clinical Liver Disease, the on-line educational journal of the AASLD from 2011 to 2017.  

    Henry C. Lin

    Dr. Lin is a pediatric hepatologist and gastroenterologist at Doernbecher Children's Hospital.  His research focus is on pediatric liver disease and assessing strategies to improve access to this specialized care.  He also conducts research on physician-caregiver-patient communication strategies and the impact on outcomes. Dr. Lin is passionate about teaching medical students and trainees. In his spare time, Dr. Lin enjoys rock climbing, barefoot running, and trying new recipes.  

    Erin Maynard

    Erin Maynard, MD, FACS, is Associate Professor of Surgery at Oregon Health and Science University, Associate Program Director of the General Surgery Residency Program,  Section Chief and Surgical Director of Liver Transplant at the Portland VA Medical Center in Portland, OR.

    Dr. Erin Maynard received her Bachelor of Science Degree at Ohio University in Athens, OH before completion of medical school at The Ohio State University, Columbus, OH. She then completed her surgical residency at Maine Medical Center in Portland, ME before completing her training in Abdominal Organ Transplantation and Hepatobiliary Surgery at Washington University in St. Louis, MO.  She went on to practice multi-organ abdominal transplant at the University of Kentucky before being recruited to Oregon Health and Science University.  Her interests at the university are focused on adult multi-organ transplantation, as well as, both benign and malignant hepatopancreaticobiliary surgery.  She is also actively engaged in resident and fellow education and focuses her research interests on clinical outcomes, hepatocellular carcinoma, and liver transplantation. 

    K. Gautham Reddy

    Gautham Reddy, MD is a transplant hepatologist and gastroenterologist who currently serves as the Associate Chief in the Section of Gastroenterology, Hepatology & Nutrition at The University of Chicago Medicine. He has an avid interest in medical education and previously served for many years as the Program Director for both the Gastroenterology Fellowship and the Transplant Hepatology Fellowship at The University of Chicago. He has been a recipient of teaching and mentorship awards and has served on multiple AASLD and ACG committees related to training and education. His research interests include novel therapeutics for rare hepatology conditions and medical education.

    Mark W. Russo

    Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. In the AASLD, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine.  He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.

    Amit G. Singal

    Dr. Singal is a Professor of Internal Medicine, Chief of Hepatology, and Medical Director of the Liver Tumor Program at UT Southwestern Medical Center in Dallas, TX. He has obtained state, DOD and NIH funding to examine the HCC care continuum, ranging from HCC prevention to screening and early detection to treatment and survivorship. Dr. Singal has published over 150 scientific papers regarding HCC screening and treatment. For his work, he has been awarded the David Bruton Professorship in Clinical Cancer Research and Blue Faery Award for Excellence in Liver Cancer Research.

    Ryan M. Taylor

    Ryan M. Taylor, MD, MS is Associate Professor of Medicine in the Division of Gastroenterology/Hepatology, Department of Internal Medicine, at the University of Kansas School of Medicine where he is Medical Director of Liver Transplantation and Medical Director of Hepatology.  After obtaining his medical doctorate at the University of Missouri-Kansas City School of Medicine, Dr. Taylor completed his residency in Internal Medicine and his fellowship in Gastroenterology/Hepatology as well as Transplant Hepatology at the University of Michigan School of Medicine in Ann Arbor.  Dr. Taylor was a 2006-2007 American Association for the Study of Liver Diseases Advanced Hepatology Award recipient.   During his fellowship training he also completed a Masters of Science degree in Clinical Research Design and Statistical Analysis through the University of Michigan School of Public Health.  

    Lisa VanWagner

    Dr. Lisa VanWagner is an Assistant Professor of Medicine-GI & Hepatology and Preventive Medicine-Epidemiology at Northwestern University in Chicago, IL.  Dr. VanWagner utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease (risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Notably, she leads the multicenter Advancing Liver Therapeutic Approaches (ALTA) Consortium Study Group for the Management of Portal Hypertension and is the lead Principal investigator for ALTA TIPS, a U.S. based longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outcomes of patients undergoing TIPS as part of their standard of care in hopes of answering key clinical questions about the utilization, outcomes and best practices surrounding TIPS as a therapeutic intervention for the complications of portal hypertension.  She is an active member of AASLD, currently serving as a member of the Practice Guidelines Committee and is an Associate Editor for Liver Transplantation and Clinical Liver Disease.

    Zobair M. Younossi

    Zobair M Younossi is the President of Inova Medicine as well as Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Falls Church, Virginia, USA. He is also Chair of Clinical Research, Inova Health System, Falls Church, Virginia. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry (Alpha Omega Alpha 1989) in Rochester, NY, USA. He then completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California, USA, while earning his master of public health degree with multiple honours from San Diego State University School of Public Health, San Diego, California, USA. He served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio, USA, before establishing the Canter for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to outcomes research in liver disease and clinical, health services and translational research in non-alcoholic fatty liver disease (NAFLD). He has served as Vice President of Research for Inova Health System and currently serves as the Chair of Research for Inova Health System. He also serves as the President and Chairman of the Board of Trustees of the Chronic Liver Disease Foundation (2018-Present) and the Board of Inova Health System Foundation (2011-Present). He was appointed by Governors T Kaine and B McDonnell of Virginia to the Board of Directors of Virginia Biotechnology Research Partnership Authority (2008-2014). He also served Virginia Tobacco & Health Research Repository (VTHRR), Board of Directors, America Heart Association, Mid-Atlantic Affiliate (2010-2012) and Board of the American College of Gastroenterology Institute for Clinical Research & Education (2013-Present). Finally, he has served on multiple committees for American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastrointestinal Association and George Mason University as well as numerous committees at Inova Fairfax Medical Campus and Inova Health System.

    Over the past 3 decades, Dr. Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. His research in both NAFLD and outcomes research is highly cited and he a highly sought-after speaker for National and International Scientific meetings. In addition to research and administrative duties, Dr. Younossi has been actively involved in teaching patients (through America Liver Foundation) students (Both medical students and post graduate students), residents and GI/Hepatology fellows. He has also served as Chair, Director or faculty of a number international scientific and CME related courses. He is also the Chair of the Global NASH Council and Global NASH Registry.

    Dr. Younossi specializes in hepatology and gastroenterology and has authored over 560 articles, 3 books, 6 journal supplements, over 25 book chapters and over 900 abstracts at the international scientific meetings. He is highly sought-after speaker providing over 430 faculty lectures in national and international meetings. His academic productivity has led to an H-index of 88. Dr.Younossi has also served as the co-editor of Liver International, Associate Editor of J of Hepatology and on the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

    Carl L. Berg

    Dr. Berg is Professor of Medicine and Medical Director of Abdominal Transplantation at Duke University.  He has been a director of liver transplant programs for more than 20 years, and trained nearly twenty transplant hepatologists over that time frame.  He has served in numerous national roles related to management of the US transplant system, including as President of UNOS.  His research interests focus on expanding the donor pool to better match organ demand, as well as utilization of organs previously considered as “marginal”.

     

    David Levi

    David Levi, MD, FACS is a transplant surgeon at Carolinas Medical Center in Charlotte, NC. He is a Professor of Surgery in the Department of Surgery at UNC-Charlotte Campus. He has been at Carolinas Medical Center since 2012.

    He received his Bachelor of Arts in Biology, graduating Magna Cum Laude with Phi Beta Kappa distinction from Wabash College in Indiana.  He completed his MD at the University Of Miami Miller School Of Medicine graduating with AOA recognition and completed his general surgery residency and transplant surgery fellowship at Jackson Memorial Hospital. He joined the faculty at the Miller School of Medicine at the University of Miami in 1999. He was promoted to the level of Clinical Professor of Surgery and was selected to the Iron Arrow Honor Society.  Dr. Levi is board certified in surgery and is a Fellow of the American College of Surgeons.  He is a member of the Southern Surgical Association, the American Society of Transplant Surgeons, and The American Association for the Study of Liver Diseases, the Transplantation Society, the International Liver Transplant Society and the Americas Hepato-Pancreato Biliary Association.  His clinical interests include liver transplantation, hepatobiliary surgery, and the multidisciplinary management of liver cancer. An author of more than 200 publications and abstracts including original manuscripts, reviews and book chapters, his academic and research interests primarily focus on the clinical aspects of liver transplantation, hepatobiliary surgery, the management of HCC, and surgical outcomes and quality.

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, Associate Professor In Residence at the University of California, San Francisco and Director of the UCSF Hepatology Clinical Research.

    Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation. Her primary research focuses on integrating core geriatric principles, such as frailty and palliative care, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients. She is the founder and principal investigator of the NIH funded Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes. She serves as an Associate Editor for the American Journal of Transplantation and Editorial Board Member of Hepatology and Liver Transplantation journals, as well as a standing member of the FDA GI Drug Advisory Committee. In 2020, she was appointed chair the AASLD Practice Guidance on Frailty, Sarcopenia, and Malnutrition. In recognition of the importance of her work, Dr. Lai has been named a NIH Beeson Scholar in Aging Research by the National Institute on Aging and was awarded the American Gastroenterological Association Young Investigator Award in 2020.

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Peter Chin-Hong

    Peter Chin-Hong is Associate Dean for Regional Campuses. He is a medical educator who specializes in treating infectious diseases, particularly infections that develop in patients who have suppressed immune systems, such as solid organ and hematopoietic stem cell transplant recipients and HIV+ organ transplant recipients. He directs the immunocompromised host infectious diseases program at UCSF. His research focuses on donor derived infections in transplant recipients and molecular diagnostics of infectious diseases in patients with suppressed immune systems. He earned his undergraduate and medical degrees from Brown University, before completing an internal medicine residency and infectious diseases fellowship at UCSF, where he is Professor of Medicine and Director of the Yearlong Inquiry Program in the School of Medicine. He was the inaugural holder of the Academy of Medical Educators Endowed Chair for Innovation in Teaching. He was a member of UNOS/OPTN Disease Transmission Advisory Committee and is Associate Medical Director of Donor Network West.

    Upon completion of this activity, learners will be able to: 

    • Discuss the diagnosis, natural history, and therapies for liver diseases leading to liver transplantation;
    • Discuss the management of patients awaiting liver transplantation;
    • Discuss the immediate post-operative and long-term management of liver transplant recipients;
    • Discuss current organ allocation policy and its effects on selecting potential liver transplant recipients.


    • Hepatologists
    • Fellows/ Trainees
    • Gastroenterologists
    • Physician Assistants
    • Surgeons

    CME 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Claiming CME Credits 

    Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by December 31, 2022. The CME evaluation will be available to you upon completion of the on-demand course.

    Maintenance of Certification
    American Board of Internal Medicine (ABIM) MOC Statement 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

    American Board of Pediatrics Maintenance of Certification (MOC) Statement
    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 9.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC points.

    Claiming MOC Points 
    Physicians seeking ABIM and/or ABP MOC Points must complete the electronic CME and MOC evaluation by December 31, 2022. MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Faculty

    Andrew Aronsohn, MD
    Nothing to disclose

    Carl Berg, MD, FAASLD      
    Scientific Consulting: Mallinckrodt Pharmaceuticals

    Peter Chin-Hong, MD          
    Grants/Research Support: Karius

    Oren Fix MD, MSc, FAASLD           
    Other (eg. Expert testimony): US Attorney (District of Oregon)

    Jaquelyn Fleckenstein, MD, FACP, FAASLD       
    Nothing to disclose

    Catherine Frenette, MD       
    Scientific Consulting: Bayer; Speakers Bureau: Bayer, Gilead

    Stevan Gonzalez, MD          
    Speakers Bureau: Abbvie, Salix

    Janice Jou, MD, MHS          
    Nothing to disclose

    Laura Kulik, MD       
    Nothing to disclose

    Jennifer Lai, MD       
    Scientific Consulting: Axcella Health, Inc.
    Advisory Committees and/or Review Panels: Biomarin (one-time only on 9/20/2019, not an ongoing relationship), Ambys Medicines, Inc. (terminated on 12/13/2019)

    Michael Leise, MD   
    Nothing to disclose

    David Levi, MD         
    Nothing to disclose

    Josh Levitsky, MD, MS, FAASLD, FAST   
    Grants/Research Support: Novartis
    Scientific Consulting: Novartis
    Speakers Bureau: Gilead

    Henry Lin, MD          
    Nothing to disclose

    Michael Lucey, MD, FAASLD         
    Grants/Research Support: Abbvie, NIAAA, PharmaSolutions, Intercept Pharma, Exact Sciences

    Erin Maynard, MD    
    Nothing to disclose

    K. Gautham Reddy, MD, FAASLD 
    Grants/Research Support: CymaBay, Genfit, Target PharmaSolutions, Arrowhead, Gilead
    Speakers Bureau: Intercept, Dova
    Leadership in Related Society: Member, Training Committee: American College of Gastoneterology

    Mark Russo MD, MPH, FAASLD    
    Other (eg. Expert testimony): S Marshall
    Speakers Bureau: All speakers bureau contracts terminate 12/31/19

    Amit Singal, MD, MS, FAASLD      
    Scientific Consulting: Bayer Pharmaceuticals, Eisai, Exelixis, Wako Diagnostics

    Ryan Taylor, MD      
    Speakers Bureau: Abbvie, Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc.

    Lisa VanWagner, MD, MSc 
    Grants/Research Support: Gore Medical
    Speakers Bureau: Salix Pharmaceuticals, Gore Medical
    Scientific Consulting: Gilead

    Zobair Younossi, MD, MPH, FAASLD       
    Advisory Committees and/or Review Panels: Gilead, BMS, Intercept, Abbvie and GSK
    Scientific Consulting: Gilead, Intercept

    Maintenance of Certification Committee

    Curtis K. Argo, MD, MS, FAASLD
    Nothing to disclose

    Raymond T. Chung, MD, FAASLD 
    Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB Alnylam
    Grant/Research Support: Abbive, Gilead Sciences, Boehringer Ingelheim, Roche, Janssen, Merck, Kaleido, Synlogic

    Debra Guss, DNP, RN, ANP-C
    Nothing to disclose 

    Steven K. Herrine, MD, FAASLD
    Grant/Research Support: Gilead, BMS, Galectin, Intercept

    Vandana Khungar, MD, MSc
    Nothing to disclose 

    Ayman A. Koteish, MD, FAASLD
    Nothing to disclose

    Ryan M. Kwok, MD
    Nothing to disclose

    Smruti R. Mohanty, MD, MS
    Advisory Committees and/or Review Panels: Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology (2009-Present) Reviewer: Hepatology, Clinical Gastroenterology & Hepatology, Digestive Disease & sciences, Post Graduate Medical Journal, World Journal of Gastroenterology World Journal of Hepatology
    Speaker's Bureau: Gilead Science, Merck, Abbvie and Intercept

    Heather M. Patton, MD, FAASLD
    Grant/Research Support: Gilead Sciences

    K. Gautham Reddy, MD, FAASLD
    Grants/Research Support: Merck, Intercept, Genfit
    Scientific Consulting: Intercept
    Speaker's Bureau: Intercept Dova
    Advisory Committees and/or Review Panels: American College of Gastroenterology 

    Mark W. Russo, MD, MPH, FAASLD
    Commercial Speaker's Bureau: Gilead, Abbvie, Intercept, Salix

    Grace L. Su, MD, FAASLD
    Stock Shareholder: My husband and son have equity interest in Applied Morphomics and Prenovo

    Ryan M. Taylor, MD
    Speaker’s Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

    Helen S. Te, MD, FAASLD
    Grants/Research Support: Conatus Pharmaceuticals, Gilead Sciences, Abbvie

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    Training and Workforce Committee

    Jessica Davis, MD
    Nothing to disclose

    Aparna Goel, MD 
    Nothing to disclose

    Nitika Arora Gupta, MD, DCH, DNB, MRCPCH
    Nothing to disclose

    Janice Jou, MD, MHS 
    Nothing to disclose

    Brian Kim, MD 
    Nothing to disclose

    Steven Krawitz, MD 
    Nothing to disclose

    Sylvia M. Lempit, MSN 
    Nothing to disclose

    Christina Cress Lindenmeyer, MD
    Scientific Consulting: Merck Manuals

    Nayan Patel, DO, MPH
    Nothing to disclose

    K. Gautham Reddy, MD, FAASLD 
    Grants/Research Support: Merck, Intercept, Genfit
    Scientific Consulting: Intercept
    Speaker's Bureau: Intercept Dova
    Advisory Committees and/or Review Panels: American College of Gastroenterology 

    Mary E. McCarthy Rinella, MD, FAASLD 
    Scientific Consulting: NGM, Gilead, Intercept, Novartis
    Data Safety Monitoring Board for Industry or Commercial Enterprise: TREAT Consortium

    Ian R. Schreibman, MD 
    Nothing to disclose

    Amy Taylor, MD 
    Nothing to disclose

    Georgios Tsoulfas, MD 
    Nothing to disclose 

    Katie Duggan, BA
    Staff Liaison
    Nothing to disclose

    AASLD Staff 

    Heather Carnahan
    Nothing to disclose

    Dominique Clayton
    Nothing to disclose

    Julie Deal
    Nothing to disclose 

    Katie Duggan
    Nothing to disclose

    Matthew D’Uva
    Nothing to disclose

    Denise Seise
    Nothing to disclose

    Suzanne Thibeault
    Nothing to disclose

    Anne Wrobel
    Nothing to disclose 

  • 2020 Webinar: Current and Future Disease Burden of HBV: Global and Regional Perspectives

    Contains 3 Component(s) Recorded On: 09/18/2020

    Webinar hosted by the Hepatitis B Special Interest Group on September 18, 2020.

    In this on-demand webinar, representative speakers from Africa including North and Sub-Saharan Africa (Mark W. Sonderup, South Africa), East Asia (Jidong Jia, China), West and South Asia (Shiv K. Sarin, India), Europe including Western and Eastern Europe (George V. Papatheodoridis, Greece), North America (Carla Coffin, Canada) and South/Central America (Adrian Gadano) will each talk on HBV disease burden and primary challenges in their respective regions. They will present the current status and predictions for the next decade. The live question and answer session, the discussion will focus on the challenges and opportunities in each region.

    Participants will be able to:

    Have a global view from regional perspectives on the current situation and future prediction of HBV disease burden and to discuss the actions (most critical/effective/cost-effective) required to improve the predictions toward a more desirable goal in the region.

    Promote the global outreach of AASLD by addressing issues that interest local audience.

    Mark W. Sonderup

    Mark Sonderup, MBChB is an associate professor in the Department of Medicine and Division of Hepatology. In 1995, he graduated from the University of Cape Town. Following his internship training, his postgraduate training was at the University of Cape Town and Groote Schuur Hospital. He obtained a Fellowship of the College of Physicians in 2002. Between 2002 and 2004, he completed a 2-year fellowship in Hepatology at the UCT/Medical Research Council Liver Research Centre and Liver Clinic at Groote Schuur Hospital, Cape Town. He briefly worked in the UK before being appointed as a Senior Specialist in the Department of Medicine and Division of Hepatology at UCT and Groote Schuur Hospital in 2007. He was granted a FRCP (London) in 2018.

    Sonderup research interests include viral hepatitis and drug induced liver injuries. He assisted in co-authoring the national viral hepatitis guidelines and elimination strategy for South Africa. Currently he serves on the WHO Strategic Advisory Committee on Viral Hepatitis.

    Shiv K. Sarin

    Shiv K. Sarin, MD, FAASLD is the senior professor of hepatology and director of Institute of Liver and Biliary Sciences (ILBS), New Delhi. He was instrumental in setting up the Institute of Liver and Biliary Sciences, under the auspices of the Govt of Delhi. He is also the director, WHO Collaborative Centre on Chronic Liver diseases and Viral Hepatitis at ILBS. He serves as adjunct faculty, Molecular Medicine at JNU due to his deep interest and contributions to translational science. He was credited with several new treatment protocols for liver diseases, specifically variceal bleeding, liver regeneration, hepatitis B and acute-on-chronic liver failure. He has more than 620 publications to his credit, edited 13 books on liver diseases and contributed 87 chapters in various medical textbooks. He has helped develop 19 major guidelines: including six major Asian Pacific Treatment Guidelines in Liver diseases.

    Sarin’s leadership roles include serving as president of the Indian Society of Gastroenterology, Indian Association for the Study of the Liver, Asian Pacific Association of Liver (APASL) and chairman steering committee of the APASL. He was awarded the prestigious 2017 Henry L. Bockus Medal by World Gastroenterology Organization. He was bestowed with Padma Bhushan by the government of India. He was a recipient of Shanti Swarup Bhatnagar Award, The World Academy of Medical Sciences (TWAS) International Prize, EASL International Recognition Award, Om Prakash Bhasin Award, Dhanvantri Medical Award, Ranbaxy Medical Sciences Award and the ‘Best Teacher’ Award. He, along with other Board of Governors, developed the ‘Vision 2015’ document for Medical Education in India during his tenure as chairman of Medical Council of India.

    George V. Papatheodoridis

    George Papatheodoridis, MD, PhD, FAASLD is a professor in medicine and gastroenterology at Medical School of National and Kapodistrian University of Athens and Director of the Academic Gastroenterology Department and the Liver Transplantation Unit of “Laiko” General Hospital of Athens, Greece. He is also the president of the Hellenic Transplant Organization. In October 1986, he was trained in Medicine at the Medical School of Athens University and graduated with excellence (9.2/10). In February 1996, he completed his PhD thesis at the Medical School of Athens University. He was trained in Gastroenterology at Tzaneion Hospital of Piraeus, Greece and had a two-year research fellowship in Hepatology at the Royal Free Hospital of London, UK (01/1997-01/1999).

    Papatheodoridis has served in many international and national associations. He is a member of EASL and American Association for Study of Liver Diseases (AASLD fellow) and founding member and treasurer of Hepatitis B and C Public Policy Association. He is president of Hellenic Foundation of Gastroenterology and Nutrition. His main research interest has been focused on viral hepatitis. He has co-authored more than 315 papers published in PubMed journals having total IF>2000 and >1600/25000 citations (h-index 62/74) in Scopus/Google Scholar. He was an associate editor of Liver International and served as an editorial board member and reviewer of several international journals. He has given more than 160 lectures, chaired over 50 lectures/round tables and presented over 300 abstracts in international meetings.

    Carla S. Coffin

    Carla Coffin, MD is an associate professor of medicine (2016), Cumming School of Medicine, University of Calgary and Medical Director of the Calgary Liver Unit, Calgary Division of Gastroenterology and Hepatology, Alberta Health Services, Alberta, Canada. She received MSc degree using the woodchuck HBV model with Professor TI Michalak and MD from Memorial University of Newfoundland, NL. She completed Internal Medicine and Gastroenterology fellowship at the University of Calgary, AB followed by an American Association for the Study of Liver Disease (AASLD) Advanced Hepatology Fellowship with Professor NA Terrault at the University of California, San Francisco.

    Coffin was a recipient of a Canadian Institutes of Health Research (CIHR) New Investigator Award (2012-2017). Her research has been supported by CIHR, AASLD, the American Gastroenterology Association, Canadian Foundation for Innovation / Alberta Advanced Education Technology, Alberta Innovates and Industry partners. She was first author on the 2012 and 2018 Canadian Association for the Study of the Liver (CASL) Hepatitis B guidelines and is Chair of the CASL Education Committee (2019-2021). She served on the World Health Organization (WHO) Expert Advisory Panel on Drug Evaluation (2015) and extended as on call WHO advisor until 2021. She has an active translational research program in hepatitis B with 90 peer-reviewed publications, has participated in more than 20 hepatitis B clinical trials and was integral to establishing the Canadian Hepatitis B Research Network.

    Adrián C. Gadano

    Adrián Gadano, MD is an associate professor in Physiology, Gastroenterology and Hepatology at the Italian Hospital School of Medicine, Argentina. He oversees the Liver Unit and Medical Director of the Transplant Unit at the Italian Hospital in Buenos Aires. He is a consultant in Gastroenterology and Hepatology and has over 25 years in the management of patients affected with hepato-biliary diseases and liver transplantation. Gadano is chief of the Research Department at the same Institution. Since the early 1990’s, he conducted, coordinated and participated in several international and national clinical trials in the fields of viral hepatitis, complications of cirrhosis, hepatocellular carcinoma and liver transplantation.

    Gadano is a member of several intra-hospital and national committees, including the Argentinian Association for the Study of Liver Diseases (AAEEH), Argentinian Society of Gastroenterology (SAGE), the Argentinian Society of Transplantation (SAT). He is also a member of the Latin American Society of Liver Diseases (ALEH), the European Association of the Study of Liver Disease (EASL) and member of the board of Journal of Hepatology. He is part of the Board of the International Club of Ascitis (ICA). He was the president of the Argentinian Society of Transplantation (SAT), Argentinian Association for the Study of Liver Diseases (AAEEH) and the ICALMA Foundation. He has published over 150 original papers in official and peer-reviewed journals, and many other journal articles, book chapters and textbooks. He presented, during the last twenty years, hundreds of original papers at conferences and has chaired numerous sessions and symposia at national and international congresses.

    Jidong Jia

    Jidong Jia, MD, PhD, is a Hepatologist and Director of the Liver Research Centre at the Beijing Friendship Hospital, Capital University in Beijing, China. He is also immediate past President of the Chinese Society of Hepatology, Past President of APASL (2009-2010), Vice President of IASL. Dr. Jia also serves as associate editor for Journal of Gastroenterology & Hepatology, Hepatology International and Liver International. His clinical interests include the chronic viral hepatitis and autoimmune liver diseases. His research work mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis.

    Mindie H. Nguyen (Moderator)

    Mindie Nguyen, MD is a professor of medicine and director for the Hepatology Fellowship and Clerkship in the Division of Gastroenterology and Hepatology and Liver Transplant at Stanford University Medical Center. She is an active clinician with a large general and transplant liver practice, and an active researcher in viral hepatitis, non-alcoholic fatty liver disease and liver cancer with over 250 publications including first or senior authorship in leading journals such as The New England Journal of Medicine, Lancet Gastroenterology and Hepatology, Gastroenterology, Journal of Hepatology and HEPATOLOGY.

    Nguyen has served as editorial/advisory board member for major journals such as Lancet Gastroenterology and Hepatology, Gastroenterology and HEPATOLOGY. She is currently Chair of the Hepatitis B Special Interest Group for the American Association for the Study of Liver Diseases (AASLD) and an Officer/Treasurer and Executive Governing Council for the International Association for the Study of Liver Diseases (IASL). She is the lead Principal Investigator for several multinational studies involving over 40 centers in the U.S. and Asia Pacific. She serves as Board of Directors or Advisors for non-profit organizations locally and nationally in the U.S; and in collaboration with the local country Ministries of Health and Sports, she has directed scientific programs of continuing medical conferences for physicians in Mongolia and Myanmar. As an active teacher and educator, she has mentored over 130 trainees from high school students to undergraduate, medical, Masters’ and PhD students in Public Health/Epidemiology, clinical residents/fellows, postdoctoral research fellows, and faculty at Assistant/Associate Professor rank from Stanford University as well as other institutions in the U.S. and overseas.

    Harry Janssen (Moderator)

    Harry Janssen, MD, PhD, FAASLD is a professor of medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in hepatology. He currently works at Toronto General Hospital as chief of hepatology and director of the Toronto Centre for Liver Disease.

    Dr. Janssen graduated from medical school in the Netherlands. During his study he spent one year as research student in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in hepatitis B. Following his training in Internal Medicine and Gastroenterology in the Netherlands, he returned to the Mayo Clinic for a Research Fellowship in Hepatology. In 2001, he became a faculty member and in 2006 he was appointed as full professor of medicine and chief of the Section Liver Diseases and Transplantation in Rotterdam. In 2013, he came to Canada where he merged three liver programs into the Toronto Centre for Liver Disease, based at the Toronto General Hospital, University Health Network.

    Dr. Janssen has coordinated numerous clinical and translational studies on treatment for chronic viral hepatitis and other liver diseases. His main research interest is cure of chronic hepatitis B. He has published more than 500 original peer-reviewed papers and many book chapters. His H-index is over 100 and he has been cited 45,000 times (Google Scholar). He has received several prestigious international awards and has mentored over 50 PhD students, of whom many have taken leadership positions in the field of hepatology or virology.

  • 2020 Webinar: Global Public Health Strategies for the Prevention of ALD in 2020

    Contains 2 Component(s) Recorded On: 09/01/2020

    Webinar hosted by the Alcohol-associated Liver Disease Special Interest Group on September 1, 2020.

    Alcohol-associated liver disease (ALD) is the leading cause of cirrhosis worldwide. Harmful drinking, especially among youth and women, is increasing.  A global alliance and discussion about effective public health strategies is needed. This webinar with a global outreach focus on ALD will involve the participation of the four major liver societies worldwide. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Alexandre Louvet

    Alexandre Louvet, MD is professor of hepatology in the gastroenterology department of the University Hospital of Lille, France, headed by Prof. Philippe Mathurin. He earned his medical degree from the University of Lille. He received his PhD degree after a fellowship in the Institut Mondor de Recherche Biomédicale in Créteil, France, where he worked on the role of the endocannabinoid system in alcoholic liver disease in mice. His clinical interests include alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma and viral hepatitis.

    He is involved in both clinical and basic research. His main topic in research is alcoholic hepatitis (natural history, treatment, disease modeling, transplantation, and pathophysiology). He has published several papers on the management of patients with severe alcoholic hepatitis. He is a member of the governing board of the French Association for the Study of the Liver (AFEF), of the editorial board of the Journal of Hepatology and a reviewer for several journals specialized in hepatology.

    Cyriac Philips

    Cyriac Philips, MD, MBBS, DM is the Clinical Lead, The Liver Unit, Cochin Gastroenterology Group, based in Kochi, and Director of Monarch Liver Lab, Department of Clinical and Experimental Gastroenterology and Hepatology at the Ernakulam Medical Center Hospital, Kochi, Kerala, India. He is a two-time Clinical Hepatology plenary awardee (2015, 2017) of the American Association for Study of Liver Diseases (AASLD) and four-time AASLD and European Association for Study of Liver (EASL) Young Investigator Award winner (2015, 2016, 2017, 2017) and recipient of the prestigious President of India Excellence in Hepatology from Institute of Liver and Biliary Sciences, New Delhi in 2016. He has published over 140 peer-reviewed studies in high impact journals including Gastroenterology; HEPATOLOGY; Journal of Hepatology; Clinical Gastroenterology and Hepatology and the American Journal of Gastroenterology. His interests and expertise include study of the gut microbiome and its modulation in severe alcoholic hepatitis and sepsis, portosystemic shunt syndrome, drug induced liver injury especially Ayurvedic herbals and infections in cirrhosis. His pioneering work in the field of liver diseases has been the introduction of healthy donor fecal transplant for severe alcoholic hepatitis and novel data on clinical outcomes, toxicology and chemical analysis of Ayurvedic herbal induced liver injury for which he received the Indian National Award for Best Paper in 2019 from The Indian Society of Gastroenterology and SpringerNature.

    Juan Pablo Arab (Moderator)

    Juan Pablo Arab, MD is Assistant Professor of Medicine at the Pontificia Universidad Catolica de Chile School of Medicine. Trained at the P. Univ Catolica, Chile and Mayo Clinic, Rochester, MN, Dr. Arab is a Gastroenterology and Hepatology specialist, Transplant Hepatologist and Physician Scientist with interest in translational and clinical research in alcohol-associated liver disease and non-alcoholic fatty liver disease. He has published more than 90 peer-reviewed papers on gastrointestinal and liver diseases in high-impact factor journals, co-authored several book chapters and delivered lectures on liver-related topics at national and international meetings. He has also participated in the generation of clinical practice guidelines for alcohol-related liver disease, nonalcoholic fatty liver disease, and hepatorenal syndrome in Latin America and regularly serves as expert reviewer of research grants and scientific research abstracts for multiple societies, funding agencies and international peer reviewed journals. Additionally, he is spearheading an international collaboration group that aims to study alcohol-related liver disease and non-alcoholic fatty liver disease. Dr. Arab is a member of the American Association for the study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Latin-American Association for the Study of the Liver (ALEH). He is currently the Secretary of the Special Interest Group on alcohol-related liver disease of the AASLD and Vice-Chairs its global outreach subcommittee. Additionally, he is the Vice-President of the Chilean Hepatology Association.

    John P. Rice (Moderator)

    John P. Rice, MD is an Assistant Professor of Medicine and the Section Chief of Hepatology in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine and Public Health. Dr. Rice completed his medical degree at the University of Nebraska College of Medicine. He completed his Internal Medicine training and served as Chief Resident at McGaw Medical Center of Northwestern University in Chicago, IL. He completed Gastroenterology and Hepatology and Transplant Hepatology fellowships at the University of Wisconsin Hospital and Clinics. He currently serves as a staff transplant hepatologist.

    Dr. Rice’s clinical and clinical research interests include management of alcohol-associated liver disease (ALD), alcohol use disorder, and liver transplant selection and liver transplant outcomes in ALD. Dr. Rice serves as the Chair of the Global Outreach subcommittee in the AASLD ALD special interest group.

  • 2020 Webinar: Dietary Recommendations for NAFLD Patients: What Do I Tell My Patients?

    Contains 2 Component(s) Recorded On: 08/19/2020

    Webinar hosted by the Non-alcoholic Fatty Liver Disease Special Interest Group on August 19, 2020.

    The purpose of this webinar is to provide the audience with the most current data regarding dietary intervention in NAFLD. The first talk "How Much Weight Should I Lose?" will focus on: he amount required for weight loss; changes in histology; and likelihood of success and exercise data. The second talk "Which Diet Should I Follow and Which Food I Should Eat or Avoid?" will include: types of diet; data on international diets; alcohol use; coffee; red meat; fructose; and others. The third talk "How Should I Start My Diet and How Would I Follow Up?" will include practical examples from NAFLD clinics. A patient with NAFLD with join the presenter during the third talk. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Manuel Romero Gómez

    Manuel Romero Gómez (Sevilla, Spain, 1967) is Full-Professor of Medicine at the University of Seville, Spain. Digestive Diseases Department at Virgen del Rocío University Hospitals. Head of group for translational research in liver diseases (SeLiver) at Institute of Biomedicine of Seville (IBIS). Coordinator of the Spanish Registry of NAFLD/NASH (HepaMET) and co-coordinator of the EASL supported European Registry of NAFLD. Principal Investigator in the Spanish Network for Research in Digestive and liver diseases (CiberEHD). He is participating actively in NASH-related European Projects: Sub-project-7 leader at European project FLIP (2010-2013), National Leader (SPAIN) at LITMUS (2017-2022) and coordinator of NASH-PI (2020-2021) an international grant.

    Member of commission 527 from ISCIII and Spanish Agency for Evaluation of Research (AEI). He received the XI Award Javier Benjumea Puigcerver in investigation, Universidad de Sevilla-Focus Abengoa, 2014. He was awarded with the Medal of The City of Seville in 2016. He has published more than 300 peer-reviewed papers on gastrointestinal and liver diseases with H-index 59. He has protected 10 patents and participated as PI in more than 20 competitive grants for research.

    Michelle Long

    Michelle Long, MD, MSc is a clinical investigator and hepatologist at the Boston University School of Medicine and Boston Medical Center. Dr. Long is the Director of the Boston Medical Center’s Nonalcoholic Fatty Liver Disease (NAFLD) Research Center and she is the Director of Clinical Research for the Section of Gastroenterology & Hepatology in the Department of Medicine. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD, including the overlap between NAFLD and cardiometabolic disease. Dr. Long is an investigator in the Framingham Heart Study where she is the Principal Investigator on a multi-year, multi-generational effort to evaluate the genetic and clinical correlates of liver fat and fibrosis as measured by transient elastography. She is the Principal Investigator for several ongoing Phase II and Phase III clinical trials in NAFLD. Dr. Long has received research funding from the National Institute of Health, Echosens Corporation, Gilead Sciences, The Doris Duke Research Foundation, and Boston University. She serves on the Liver-Biliary Council for the American Gastroenterological Association and on the Training and Workforce Committee for the American Association for the Study of Liver Diseases. Dr. Long is also an Associate Editor for Liver International.

    Zachary Henry

    Zachary Henry, MD is a transplant hepatologist at the University of Virginia in Charlottesville, Virginia. He works in our general hepatology and liver transplant clinics. In 2015, Dr. Henry started a specific clinic for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that is focused on lifestyle interventions for weight management. This clinic is a multi-disciplinary clinic run in conjunction with UVA endocrinology and cardiology specialists to approach related issues of metabolic syndrome in these patients. To that end , he underwent training in Obesity Medicine in 2017 and became certified by the American Board of Obesity Medicine in 2018. His research interests focus on lifestyle modfications for non-alcoholic fatty liver disease and the potential impact different groups of medications may have on these interventions.

    Wayne Eskridge

    Wayne Eskridge worked as an electrical engineer in software and electronics through a 50-year professional career. Eskridge held executive positions in both public and private corporations with worldwide responsibilities, and from startups to Fortune 500 firms. He was first diagnosed with liver disease in 2010, which progressed to cirrhosis by 2015. He has successfully managed his disease and as a result he became aware of an acute need for an educational resource from a patient perspective. His desire to help others avoid his experiences led him to the decision to become a patient advocate and to create the Fatty Liver Foundation.

    Mazen Noureddin (Moderator)

    Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He is a faculty at the Division of Digestive and Liver Diseases which was ranked #2 in gastroenterology and gastrointestinal surgery in the 2019 US News and World Report.

    His focus is on clinical and translational research in the area of NAFLD. Dr. Noureddin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He has given many invited lectures on NAFLD/NASH at national (e.g. American Gastroenterological Association, AASLD) and international society meetings and serves on several steering committees / advisory boards for industry.

  • Fundamentals of Liver Disease - Non-Alcoholic Fatty Liver Disease (NAFLD) & Non-Alcoholic Steatohepatitis 2.0

    Contains 31 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:
    NAFLD: Diagnosis and Identification of Those at Risk of Disease Progression
    Pathogenesis of Non-alcoholic Steatohepatitis
    Non-Invasive Determination of Advanced Disease in NAFLD
    Lifestyle Interventions: Setting Goals and Recommendations
    Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
    Bariatric Surgery: Is the Cure for NASH in the OR?
    Managing NASH Cirrhosis and Assessment for Liver Transplant
    Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
    Emerging Treatments for Non-Alcoholic Steatohepatitis

    Release date: June 15, 2020
    Expiration date: June 14, 2023
    Time to complete each module: 30 minutes

    CREDITS OFFERED

    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Continuing Education (CE): For a maximum of 4.50 Contact Hour
    You may only earn one Continuing Education Credit type- either CE or CME

    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
    -9 online, narrated modules 15 to 20 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete necessary components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION
    For questions on CME and  MOC content or LiverLearning®, contact online_education@aasld.org
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objective:
    • Identify patients with liver disease, specifically NASH/NAFLD
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for NASH/NAFLD
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points
    Continuing Education (CE): For a maximum of 4.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS
    Physicians and other health care professionals for a maximum of 4.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by June 14, 2023

    CLAIMING ABIM MOC POINTS 
    Physicians seeking ABIM MOC credit must complete the enduring material by June 14, 2023. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through July 2023 for individuals who successfully complete MOC.

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.50 contact hours for this enduring continuing education material must be completed by June 14, 2023

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-test

                 o    Watch video presentation

                 o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Mary E. Rinella, MD, FAASLD
    Faculty
    Consulting: AbbVie, NuSirt, NGM Biopharmaceuticals, Novartis, Gilead, Intercept, Genfit, Enanta, BMS, Immuron, CymaBay, Merck, Viking, Madrigal, Genesis, Metacrine, Allergan, Thetis, Fractyl, 3vBio, Coherus, Terns, Boehringer Ingelheim and Takeda
    Editorial Board: Hepatology, Clinical Liver Disease (guest associate editor), Seminars in Liver Disease (associate editor in 2017)

    Arun J. Sanyal, MD, MBBS
    Faculty
    Consulting: Novartis, Merck, BMS, Boehringer Ingelheim, Nitto Denko, Tobira, Intercept, Genfit, Aredelyx, Akarna, Syntlogic, Fractyl, Pfizer, Jannsen, Exalenz, Novo Nordisk, Nordic Bioscience, Lilly
    Grant/research support: Intercept, Gilead, Tobira, Novartis, Astra Zeneca, Merck, BMS
    Stock Options: Genfit
    President of Sanyal Bio

    Leon A. Adams, MBBS, FRACP, PhD
    Faculty
    Patents regarding Hepascore
    Employer has a licensing agreement with Quest Diagnostics regarding its commercialization

    Brent Neuschwander-Tetri, MD
    Faculty
    Consulting: Allergan, Allysta, Arrowhead, ARTham, Axcella, Blade, Boehringer-Ingelheim, Bristol-Myers Squibb, Conatus, Consynance, Cymabay, Durect, Enanta, Ferring, Fortress, Gelesis, Genfit, Gilead, High Tide, Histolndex, Intercept, Lipocine, Llama, Madrigal, Medimmune, Merck, Metacrine, Mundipharma, NGM, pH-Pharma, Prometheus and Siemens
    Grants/research support: Allergan, BMS, Cirius, Cymabay, Enanta, Galectin, Genfit, Gilead, Intercept, Madrigal, NGM and Prometheus

    Kathleen E. Corey, MD, MPH, MMSc
    Faculty
    Nothing to disclose

    Philippe Mathurin, MD, PhD
    Faculty
    Financial Interests: MSD, Abbvie, Gilead Sciences, Bristol-Myers Squibb, Verlyx, Intercept, Janssen-Cilag and Bayer Healthcare pharmaceutical companies

    Kymberly D. Watt, MD

    Faculty
    Co-investigator for industry studies supported by Conatus, Intercept Pharmaceuticals and Gilead

    Dawn M. Torres, MD
    Faculty
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD
    Faculty
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Sanjeeva Arora, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author

    Guadalupe Garcia-Tsao, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Advisory Board: Intercept, Conatus
    Scientific Consultant/Advisor to Industry or Commercial Enterprises, including Development of Education Presentations: Conatus, Galectin
    Research Grants: Intercept

    Leslie Hayes, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Minhhuyen Nguyen, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Vicki Shah, PA
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board

    Raj Vuppalanchi, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, MSN
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.